$707 Million is the total value of Column Group LLC's 5 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RVMD | Sell | Revolution Medicines Inc | $106,242,000 | -35.3% | 3,347,245 | -6.5% | 15.04% | -4.4% |
| NRIX | Exit | Nurix Therapeutics Inc | $0 | – | -5,383,333 | -100.0% | -16.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NGM Biopharmaceuticals Inc | 12 | Q3 2023 | 52.5% |
| Revolution Medicines Inc | 12 | Q3 2023 | 36.3% |
| RAPT Therapeutics Inc | 12 | Q3 2023 | 29.6% |
| ORIC Pharmaceuticals Inc. | 12 | Q3 2023 | 14.6% |
| Tenaya Therapeutics, Inc. | 9 | Q3 2023 | 24.2% |
| Surrozen, Inc. | 9 | Q3 2023 | 8.2% |
| eFFECTOR Therapeutics Inc | 9 | Q3 2023 | 6.9% |
| Constellation Pharmaceuticals Inc. | 3 | Q2 2021 | 12.6% |
| Nurix Therapeutics Inc | 2 | Q1 2021 | 16.1% |
| Gritstone Oncology Inc | 1 | Q4 2020 | 0.3% |
View Column Group LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-07-24 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 4 | 2022-05-27 |
| 4 | 2022-05-25 |
| 13F-HR | 2022-05-16 |
View Column Group LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.